Farms.com Home   News

CGC pays out $1.2 million in compensation for unpaid deliveries to Zeghers Canada

The Canadian Grain Commission has finished reviewing producer compensation claims for unpaid deliveries to  Zeghers Seed Inc. (operating as Zeghers Canada).

The company held a grain dealer licence and a primary elevator licence for an elevator located in Holland, Manitoba.

 Producers who were not paid for  grain delivered to Zeghers Seed Inc. will be fully compensated for their eligible claims through the Canadian Grain Commission’s Safeguards for Grain Farmers Program.

The Canadian Grain Commission will issue full compensation for 27 eligible claims totalling over $1.2 million from the company’s security to these producers.

The CGC revoked the licences of Zeghers Seed Inc. on March 25, 2024.

Chief Commissioner David Hunt says the Canadian Grain Commission is committed to ensuring producers are fairly compensated for their deliveries. 

"Our Safeguards for Grain Farmers Program plays a key role in securing payments for producers, and we are pleased to be able to provide 100% coverage of eligible claims for unpaid deliveries to Zeghers Seed."

Source : Pembinavalley online

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.